Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer

A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)

NCT01183858 ·Status: COMPLETED ·Phase: PHASE3

An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer

NCT01194050 ·Status: COMPLETED

A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer

NCT01066884 ·Status: COMPLETED ·Phase: PHASE4

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT02013219 ·Status: COMPLETED ·Phase: PHASE1

A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations

NCT01310036 ·Status: COMPLETED ·Phase: PHASE2

An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer

NCT01535729 ·Status: COMPLETED

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

NCT00085839 ·Status: COMPLETED ·Phase: PHASE2

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)

NCT01378962 ·Status: COMPLETED ·Phase: PHASE2

An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00949910 ·Status: COMPLETED ·Phase: PHASE4

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

NCT00988169 ·Status: TERMINATED ·Phase: PHASE2

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

NCT03805841 ·Status: TERMINATED ·Phase: PHASE2

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

NCT01372384 ·Status: COMPLETED ·Phase: PHASE2

A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

NCT00139620 ·Status: COMPLETED ·Phase: PHASE1

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations

NCT01287754 ·Status: COMPLETED ·Phase: PHASE4

A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT01996332 ·Status: COMPLETED ·Phase: PHASE2

Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

NCT00294762 ·Status: COMPLETED ·Phase: PHASE2

Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

NCT06830694 ·Status: RECRUITING ·Phase: PHASE2

An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer

NCT01488331 ·Status: COMPLETED

Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)

NCT02006043 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)

NCT03126799 ·Status: UNKNOWN ·Phase: PHASE2

Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC

NCT06690541 ·Status: NOT_YET_RECRUITING

A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy

NCT01174563 ·Status: COMPLETED ·Phase: PHASE2

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

NCT01221077 ·Status: COMPLETED ·Phase: PHASE2

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC

NCT04455594 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

NCT05047250 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3